FREE Daily Stock Alerts From Stock-PR.com
GreenHouse Holdings, Inc. announced the results of operations for the third quarter of Fiscal Year 2010 and is providing a shareholder update.
2010 Operational Highlights:
- Acquired Life Protection Inc., (NYSE:LPI) a subsidiary that provides innovative training, support, design and construction of facilities and services to meet the needs of the U. S. Government, military, and law enforcement agencies.
- Signed multiple contract awards for its Life Protection (LPI) Governmental Services Division, totaling $6 million.
*The governmental contracting entities include the U.S. Marine Corps School of Dynamic Entry in Quantico, VA and the U.S. Army Schofield Barracks Range Support in Honolulu, HI.
- Announced that PepsiCo will partner with GreenHouse to utilize Southern California Edison's Automated Demand Response program at its Buena Park bottling plant.
- Signed Letter of Intent to acquire Control Engineering, Inc (NYSEMKT:CEI). Headquartered in Costa Mesa, California and serving clients globally, CEI provides turnkey automation and control solutions including engineering, installation and integration services.
*Experts in multiple technologies and applications, CEI's client base includes recognizable brands from a wide range of industries including pharmaceutical, food, and beverage, utility, military and consumer goods.
- Shareholder's equity increased to $2.9 million from a deficit of approximately $2 million as of 12/31/09.
- The Company is completing the necessary steps to Up-List its shares to a senior U.S. stock exchange.
*In order to facilitate the transition, GreenHouse established an independent board and appointed PKF, a nationally recognized accounting firm, as their SEC auditors.
"Management is pleased with our operational and financial growth," stated Chris Ursitti, CEO of GreenHouse Holdings. "Life Protection Inc. and the pending acquisition of Control Engineering, Inc. will provide the company with a strong foundation of growth while positioning us as a market leader within the energy efficiency and load reduction arena. In addition to expanding operations within the residential, commercial and governmental markets, we also anticipate expansion from our industrial clients as we deploy our Automated Demand Response products. We are confident that these developments will rapidly increase earnings, expand margins and allow us to achieve our ultimate goal of increased shareholder value."
MusclePharm(NYSE:R) Corporation (OTCBB:MSLP), one of the fastest growing nutritional supplement companies in the United States, recently announced it has reached an agreement to raise $1.4 million through a convertible promissory note and registration agreement with an accredited investor.
“We are very pleased with the successful completion of the agreement with the investor and believe this capital will support our capital requirements for growth,” commented Brad Pyatt, MusclePharm’s Chief Executive Officer. “We appreciate our investor’s confidence in MusclePharm as we continue to execute our long-term growth strategy.”
This capital raise, combined with the previously released fulfillment agreement with IVitals, further enhances the Company’s overall financial strength for future long-term profitable growth. Management will continue to focus on the development, sales & marketing of MusclePharm’s growing portfolio of nutritional supplement products.
Vitacost.com, Inc. (Nasdaq:VITC) announced on December 07, 2010, as previously reported in the Company’s Current Report on Form 8-K dated November 15, 2010, that the Company’s Audit Committee of its Board of Directors (the “Audit Committee”), in consultation with its independent professional advisors and consultants, commenced with the authorization of the full Board of Directors, an internal review of the methodologies and procedures used by the Company to calculate the value, for financial reporting purposes, of certain non-cash stock-based compensation grants and awards to Company employees made just prior to the completion of the Company’s initial public offering in September 2009 (the “IPO”), as well as a review of the manner in which certain non-cash expense items were classified in connection therewith (the “Internal Review”).
Vitacost.com, Inc. operates as an online retailer and direct marketer of health and wellness products. It offers dietary supplements, such as vitamins, minerals, herbs or other botanicals, amino acids, and metabolites, as well as cosmetics, organic body and personal care products, sports nutrition, and health foods. The company sells its products directly to consumers through its Web site, vitacost.com, as well as through catalogs. It offers approximately 30,000 products from 1,600 third-party brands; and its own proprietary brands.
American Pacific Corp. (Nasdaq:APFC) announced that it will release its Fiscal 2010 year-end and fourth quarter financial results on Thursday, December 16, 2010, immediately after the market closes. Joseph Carleone, President & Chief Executive Officer and Dana Kelley, Vice President, Chief Financial Officer and Treasurer, will host a related investor teleconference/webcast at 1:30 p.m. Pacific Time.
American Pacific Corporation primarily manufactures fine and specialty chemicals and propulsion products in the United States. It operates in four segments: Fine Chemicals, Specialty Chemicals, Aerospace Equipment, and Other Businesses. The Fine Chemicals segment manufactures active pharmaceutical ingredients and registered intermediates. Its pharmaceutical ingredients are used in drugs with indications in three primary areas: anti-viral, oncology, and central nervous system.
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCCP) announced on December 05, 2010, the presentation of new preclinical data for CYC065, a novel, orally-available, cell cycle kinase inhibitor. The data were reported at a poster presentation at the 52nd Annual Meeting of the American Society of Hematology (NYSE:ASH) in Orlando, Florida."We are encouraged by the prospects of new multiple myeloma treatments, such as CYC065, that may act by modulation of cell cycle mechanisms, potentially expanding the range of therapeutic alternatives available to patients," said Noopur Raje, M.D., Director of the Center for Multiple Myeloma at Massachusetts General Hospital Cancer Center in Boston and Associate Professor of Medicine at Harvard Medical School.
Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancer and other serious disorders. Its orally-available drugs in clinical development include Sapacitabine (CYC682), an oral nucleoside analogue, which is in phase II studies for the treatment of hematological malignancies.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer).Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received ten thousand dollars in cash and anticipates another ten thousand dollars in cash from the company for 60 days of advertisement services for Green House Holdings, Inc. (OTCQB:GRHU). In addition to the cash, Crown Equity Holdings Inc. (OTCPK:CRWE) also anticipates receiving 20,000 shares of 144 restricted stocks from a third party. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP)
Sign Up For Free Stock Alerts At http://stock-pr.com/signup
The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone.